PDT Partners LLC boosted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 27.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 508,431 shares of the company's stock after purchasing an additional 109,324 shares during the quarter. Roivant Sciences comprises approximately 0.5% of PDT Partners LLC's holdings, making the stock its 17th largest holding. PDT Partners LLC owned 0.07% of Roivant Sciences worth $6,015,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also bought and sold shares of the stock. Russell Investments Group Ltd. lifted its position in shares of Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after buying an additional 1,948 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new position in Roivant Sciences during the fourth quarter valued at $39,000. GAMMA Investing LLC increased its holdings in shares of Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after buying an additional 1,288 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Roivant Sciences by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after acquiring an additional 1,507 shares in the last quarter. Finally, Wells Fargo & Company MN raised its position in Roivant Sciences by 84.1% during the fourth quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock valued at $89,000 after purchasing an additional 3,426 shares during the period. Hedge funds and other institutional investors own 64.76% of the company's stock.
Roivant Sciences Stock Down 0.9 %
ROIV traded down $0.10 during trading hours on Friday, reaching $11.48. 8,767,529 shares of the company's stock traded hands, compared to its average volume of 5,524,147. The firm has a 50-day moving average price of $10.42 and a 200 day moving average price of $11.13. The firm has a market capitalization of $8.19 billion, a PE ratio of -76.53 and a beta of 1.25. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $13.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Equities analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.
Analyst Ratings Changes
ROIV has been the topic of several recent research reports. HC Wainwright restated a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a report on Monday, April 21st. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th.
Check Out Our Latest Analysis on Roivant Sciences
Insiders Place Their Bets
In related news, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $10.22, for a total value of $1,022,000.00. Following the completion of the sale, the chief operating officer now directly owns 1,116,345 shares in the company, valued at $11,409,045.90. The trade was a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Rakhi Kumar sold 227,500 shares of the company's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the sale, the chief accounting officer now directly owns 163,264 shares of the company's stock, valued at approximately $1,702,843.52. This trade represents a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,395,541 shares of company stock worth $14,922,538 in the last three months. Corporate insiders own 7.90% of the company's stock.
About Roivant Sciences
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
